Torthaí cuardaigh - Matthias Trampisch
- 1 - 3 toradh as 3 á dtaispeáint
-
1
Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial de réir Ronald Eccles, Birgit Winther, Sebastian L. Johnston, Patrick Robinson, Matthias Trampisch, Stephan Koelsch
Foilsithe / Cruthaithe 2015Artigo -
2
Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis de réir Lisa Lancaster, Jonathan Goldin, Matthias Trampisch, Grace Hyun J. Kim, Jonathan Ilowite, L. Homik, David Hotchkin, Mitchell Kaye, Christopher J. Ryerson, Nesrin Moğulkoç, Craig Conoscenti
Foilsithe / Cruthaithe 2020Artigo -
3
Segurança e tolerabilidade de Nintedanibe em pacientes com fibrose pulmonar idiopática no Brasil de réir Carlos Alberto de Castro Pereira, José Antônio Baddini Martínez, Bruno Guedes Baldi, Sérgio Jezler, Adalberto Sperb Rubin, Rogério Rufino, Gilmar Zonzin, Manuel Quaresma, Matthias Trampisch, Marcelo Fouad Rabahi
Foilsithe / Cruthaithe 2019Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Internal medicine
Medicine
Adverse effect
Alternative medicine
Clinical endpoint
Gastroenterology
Idiopathic pulmonary fibrosis
Lung
Nintedanib
Pathology
Placebo
Randomized controlled trial
Clinical trial
Common cold
Diffusing capacity
Discontinuation
Immunology
Lung function
Nasal administration
Nasal spray
Nausea
Respiratory system
Rhinovirus
Tolerability
Vital capacity